SER (Serina Therapeutics) 3-Year RORE % : -41.44% (As of Mar. 2026)


SER Serina Therapeutics Inc SER
12 GF Score
Price $1.97
! 1 Warning Sign
View Full Analysis

What is Serina Therapeutics 3-Year RORE %?

Serina Therapeutics SER +8.84% 12 3-Year RORE % is -41.44 as of Mar. 2026. GuruFocus rates SER with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,295 Biotechnology companies, Serina Therapeutics ranks worse than 76.6% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Serina Therapeutics's 3-Year RORE % for the quarter that ended in Mar. 2026 was -41.44%.

The industry rank for Serina Therapeutics's 3-Year RORE % or its related term are showing as below:

SER's 3-Year RORE % is ranked worse than
76.6% of 1295 companies
in the Biotechnology industry
Industry Median: -11.53 vs SER: -41.44

Serina Therapeutics  (AMEX:SER) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Serina Therapeutics 3-Year RORE % Related Terms


Serina Therapeutics 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Serina Therapeutics's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Serina Therapeutics 3-Year RORE % Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
0.00 0.00 0.00 0.00 41.57

Serina Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 29.54 40.97 41.57 -41.44

SER vs NRSN, IGC, PVCT: 3-Year RORE % Comparison

For the Biotechnology subindustry, Serina Therapeutics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Serina Therapeutics 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Serina Therapeutics's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Serina Therapeutics's 3-Year RORE % falls into.


SER
12GF Score
Serina Therapeutics Inc SER
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Serina Therapeutics 3-Year RORE % Calculation

Serina Therapeutics's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -2--4.916 )/( -7.036-0 )
=2.916/-7.036
=-41.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -41.44 mean?
Serina Therapeutics (SER) has a 3-Year RORE % of -41.44 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Serina Therapeutics and its competitors. According to the industry distribution chart, Serina Therapeutics ranks #992 out of 1295 companies in the Biotechnology industry, placing it in the top 76.6%.
Is Serina Therapeutics' 3-Year RORE % too high?
Serina Therapeutics' current 3-Year RORE % is -41.44. Based on the distribution chart, Serina Therapeutics ranks #992 out of 1295 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Serina Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Serina Therapeutics' 3-Year RORE % compare to NRSN and IGC?
According to the Biotechnology industry distribution chart, Serina Therapeutics ranks #992 out of 1295 companies for 3-Year RORE %. This places Serina Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Serina Therapeutics and its competitors. Serina Therapeutics's current 3-Year RORE % is -41.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Serina Therapeutics stock overvalued right now?
Serina Therapeutics (SER) has a current 3-Year RORE % of -41.44. The current 3-Year RORE % is -41.44. Serina Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Serina Therapeutics (SER), the current 3-Year RORE % is -41.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Serina Therapeutics Business Description

Other Exchanges 2BO:Germany
Address 601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
12GF Score

Get the complete analysis for SER

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.97
Price